Angiex is pioneering the development of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs), a novel therapeutic approach aimed at addressing the critical challenges associated with cancer lethality. The company's lead product, AGX101, is designed to target TM4SF1, a protein that is highly expressed in both tumor cells and the endothelial cells of tumor blood vessels. This targeting mechanism allows AGX101 to effectively deliver chemotherapeutic agents directly to the nucleus of cancer cells, enhancing the drug's efficacy while minimizing common side effects associated with traditional cancer therapies. The ND-ADC platform not only aims to kill malignant cells but also seeks to activate the immune response against tumors and disrupt the blood vessels that supply them, thereby tackling multiple hallmarks of cancer.

Angiex's innovative approach leverages its proprietary Nuclear Delivery Platform™, which includes TM4SF1-directed antibodies and a unique site-specific conjugation method. This platform enables the conjugation of a diverse range of drug payloads, including traditional chemotherapies and newer modalities like protein degraders and RNA. By ensuring that drug payloads are delivered specifically to TM4SF1-expressing cells, Angiex aims to reduce the risk of adverse effects while maximizing therapeutic impact. The company is currently advancing AGX101 through clinical trials and is actively developing a pipeline of additional ND-ADCs, reflecting its commitment to transforming cancer treatment and improving patient outcomes.

United States

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located. 

Angiex

Company Details